Nektar Therapeutics (NKTR) shares were up over 16% in recent Monday trading after the company said it agreed to sell its Huntsville, Alabama, manufacturing facility and PEGylation reagent supply business to Ampersand Capital Partners for $90 million.
The consideration comprises $70 million in cash and a $20 million equity position in a newly created Ampersand portfolio company that will house the Huntsville-based facility, according to the statement.
In addition, Nektar said it will sign manufacturing supply agreements with the new Ampersand company for its PEG reagent needs.
The deal is expected to close by Dec. 2 and Nektar said it will retain all rights to current and future royalty streams and milestones related to its existing PEGylated product license deals.
Nektar Chief Executive Howard Robin said the sale streamlines the company's operations and extends its cash runway into Q4 2026.
Price: 1.43, Change: +0.20, Percent Change: +16.26
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.